Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

TA218- Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - Appendix A - provisional matrix of stakeholders

TA218- Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - Appendix A - provisional matrix of stakeholders

TA218- Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - Appendix A - provisional matrix of stakeholders
24 February 2014
(96.7 Kb 28 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 17 February 2014